Moderna Merck Vaccine Cuts Melanoma Risk
A late-stage trial shows that Moderna and Merck's mRNA cancer vaccine combined with Keytruda cuts melanoma death or recurrence risk by 42 percent. Despite the positive clinical results, company shares fell following the data release.
Xurve View
Insights:
Xurve View
MODERNA INC and MERCK & CO. INC. said an mRNA cancer vaccine combined with immunotherapy cut melanoma death or recurrence risk by 42%. The Phase 3 trial results demonstrated a 38% reduction in cancer spread among more than 1,100 patients. Investors reacted sharply despite the positive clinical data, pushing shares lower amid concerns over commercial pricing potential.
